v2.4.0.6
Stock-Based Compensation Expenses
 3 Months Ended
Mar. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation Expenses
STOCK-BASED COMPENSATION EXPENSE
The following table summarizes the stock-based compensation expense included in our Condensed Consolidated Statements of Income (in thousands):
 
Three Months Ended
 
March 31,
 
2012
 
2011
Cost of goods sold
$
2,101

 
$
2,644

Research and development expenses
118,622

 
16,720

Selling, general and administrative expenses
121,945

 
30,106

Stock-based compensation expense included in total costs and expenses
242,668

 
49,470

Income tax effect
(13,064
)
 
(12,856
)
Stock-based compensation expense, net of tax
$
229,604

 
$
36,614


Total stock-based compensation for the three months ended March 31, 2012, included $100.1 million and $93.8 million in research and development expenses and selling, general and administrative expenses, respectively, related to the acceleration of unvested stock options in connection with the acquisition of Pharmasset.